ELI LILLY AND COMPANY Payments to Acquire Productive Assets
ELI LILLY AND COMPANY (LLY) reported Payments to Acquire Productive Assets of $1.35 billion for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-01.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireProductiveAssets · last filed 2022-11-01
- ELI LILLY AND COMPANY payments to acquire productive assets for the quarter ending 2022-09-30 was $617.20M, a 83.25% increase year-over-year.
- ELI LILLY AND COMPANY payments to acquire productive assets for the quarter ending 2022-06-30 was $371.00M, a 2.70% decline year-over-year.
- ELI LILLY AND COMPANY payments to acquire productive assets for the quarter ending 2022-03-31 was $365.40M, a 21.68% increase year-over-year.
- ELI LILLY AND COMPANY payments to acquire productive assets for the quarter ending 2021-09-30 was $336.80M, a 14.32% decline year-over-year.
| Period end | Payments to Acquire Productive Assets 3 month | Payments to Acquire Productive Assets 6 month | Payments to Acquire Productive Assets 9 month |
|---|---|---|---|
| 2022-09-30 | $617.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $988.20M derived: sum of 2 quarters · filed 2022-11-01 | $1.35B 10-Q · filed 2022-11-01 |
| 2022-06-30 | $371.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $736.40M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $365.40M 10-Q · filed 2022-04-29 | ||
| 2021-09-30 | $336.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $718.10M derived: sum of 2 quarters · filed 2022-11-01 | $1.02B 10-Q · filed 2022-11-01 |
| 2021-06-30 | $381.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $681.60M 10-Q · filed 2022-08-04 | |
| 2021-03-31 | $300.30M 10-Q · filed 2022-04-29 | ||
| 2020-09-30 | $393.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-27 | $674.90M derived: sum of 2 quarters · filed 2021-10-27 | $933.20M 10-Q · filed 2021-10-27 |
| 2020-06-30 | $281.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $540.10M 10-Q · filed 2021-08-03 | |
| 2020-03-31 | $258.30M 10-Q · filed 2021-04-30 | ||
| 2019-09-30 | $263.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $503.70M derived: sum of 2 quarters · filed 2020-10-28 | $707.40M 10-Q · filed 2020-10-28 |
| 2019-06-30 | $240.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $444.00M 10-Q · filed 2020-07-31 | |
| 2019-03-31 | $203.70M 10-Q · filed 2020-05-01 | ||
| 2018-09-30 | $816.30M 10-Q · filed 2019-10-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |